Category: Partners

Now Open for the Scientific Community to Test and Validate for Mankind

MIAMI BEACH, FL / ACCESS Newswire / August 26, 2025 / The Tripathi Foundation announces the release of the Universal Unity Script, a framework that derives physical, chemical, biological, and mathematical laws from two core assumptions. The script has been designed for scientists and researchers and is offered openly for rigorous testing and debate.

The framework produces derivations of Newtonian gravity, Maxwell’s equations, QCD confinement, cosmological dynamics, black-hole thermodynamics, thermodynamic chemistry, metabolic scaling in biology, and mathematical invariants. It integrates verification against internal benchmarks and external datasets, ensuring that every step can be validated independently.

Personal Statement

“We could tell you that we are the smartest people in the world, but we are not. We are fairly simple people, more like Mr. Magoo, who accidentally stumbled on something special. What we have found is beyond our understanding, and we need your help. We are not vested in the outcome either way, true or false – we are simply curious, and we share because it is our intrinsic nature. If this framework is correct, we could have kept it private and become among the richest in the world. But that seems unnecessary, because the moment is already perfect.”

Deliverables Summary

The Unity Script, when executed, provides:

• Unified Equations (Origin → Meta-Layer → Forces).

• Physics Reductions: Newton, Maxwell/QED, QCD, cosmology, black holes.

• Cross-Domain Validations: chemistry, biology, mathematics.

• Falsifiable Predictions tested against internal and external datasets.

• PASS/FAIL Report Card for transparency.

Testing

To our knowledge, the script has been successfully tested on ChatGPT, Grok, and Claude. It is now presented to the scientific community with an open invitation: test it, challenge it, refine it.

Disclaimer

This release is intended solely for physicists, mathematicians, chemists, biologists, and researchers. Verification, falsification, and application rest with the global scientific community.

Humbly brought to you by the Tripathi Foundation Inc.

SOURCE: Tripathi Foundation Inc

View the original press release on ACCESS Newswire

VRCCO Welcomes New Specialists and Expanded Service Offerings

BEND, OREGON / ACCESS Newswire / August 26, 2025 / The Veterinary Referral Center of Central Oregon, a trusted leader in advanced veterinary medicine, is proud to announce the addition of a board-certified veterinary anesthesiologist in September 2025. Dr. Lily Davis, DVM, CVA, DACVAA, will be joining the VRCCO organization, currently based out of Bend, Oregon.

Veterinary anesthesiologists are specially trained veterinarians who focus on the administration of anesthesia, pain management, and providing overall care during surgical procedures for animals. Anesthesiologists play a critical role in ensuring the safety and well-being of animals by designing customized anesthetic protocols based on the individual needs of each patient. These personalized protocols consider age, species, health status, and even breed-specific characteristics (such as brachycephalic breeds) to reduce the risks of adverse effects and enhance a pet’s recovery.

Anesthesiologists also play a pivotal role in post-operative care in an advanced medical setting. They implement complex pain management strategies to effectively control pain while minimizing potential side effects. This comprehensive pain control is vital for animal recovery and can dramatically improve the quality of life for pets post-surgery.

VRCCO remains committed their ongoing growth and progress, in their effort to provide the best, most advanced, personalized pet care for patients from the Bend community as well as those who travel from across the country. Dr. Lily Davis’s expertise and field research will ensure the continued advancement of patient care, allowing animals to receive the best possible treatment options while leading to more successful outcomes and improved overall patient well-being.

In addition to Dr. Davis, VRCCO is pleased to welcome rehabilitation veterinarian Dr. Chelsey Lindberg, BVMS, MRCVS, CCRT, CVMA, and veterinary dermatologist Dr. Emily Gale, DVM, DACVD, to their team of specialists. VRCCO Dermatology will also be extended to a five-day, Monday-Friday service.

Moreover, recognizing the growing needs for accessible veterinary care, VRCCO now offers telemedicine informational appointments for total hip replacements and certain oncologic cancer diagnoses. These virtual appointments provide pet parents with essential information to make informed decisions while streamlining the path toward surgery or treatment with VRCCO.

As the field of veterinary medicine continues to evolve, the Veterinary Referral Center is dedicated to the continuous improvement of care through innovation with advanced technology, highly trained specialists, and a dedicated, compassionate team. These efforts solidify VRCCO’s reputation as a leader in animal healthcare, poised to set new benchmarks of excellence in the coming years. For more information on the specialties offered at VRCCO, please contact 541-209-6960 or email info@vrcvet.com.

The Veterinary Referral Center offers the most advanced emergency and specialty care options to members of the Central Oregon community and beyond. VRCCO was formed with a single goal in mind: to provide the highest level of personalized pet care. With over a decade of devotion to the veterinary field and a lifetime of being animal lovers, they know how important it is to be your pet’s hero.

Contact Information

Katie Sedivec
Marketing Director
marketing@vrcvet.com
541-209-6960

SOURCE: Veterinary Referral Center of Central Oregon

View the original press release on ACCESS Newswire

HOUSTON, TEXAS / ACCESS Newswire / August 26, 2025 / XCF Global, Inc. (“XCF”) (Nasdaq:SAFX), a key player in decarbonizing the aviation industry through Sustainable Aviation Fuel (“SAF”), today announced that on August 21, 2025 it received a notification letter (the “Notice”) from Nasdaq indicating that XCF was not in compliance with Nasdaq Listing Rule 5250(c)(1) due to the delay in XCF filing its Quarterly Report on Form 10-Q for the period ended June 30, 2025 (“Q2 Form 10-Q”). The Notice has no immediate effect on the listing of XCF’s Class A Common Stock, which will continue to trade on Nasdaq under the symbol “SAFX.”

Under Nasdaq rules, XCF has 60 calendar days, or until October 20, 2025, to submit a plan to regain compliance. If XCF’s plan is accepted, Nasdaq can grant an exception of up to 180 calendar days from the due date of the Q2 Form 10-Q, or until February 17, 2026, to regain compliance.

XCF is in the process of completing the Q2 Form 10-Q and currently expects to file the Q2 Form 10-Q with the Securities and Exchange Commission no later than September 30, 2025.

About XCF Global, Inc.

XCF Global, Inc. is a pioneering sustainable aviation fuel company dedicated to accelerating the aviation industry’s transition to net-zero emissions. XCF is developing and operating state-of-the-art clean fuel SAF production facilities engineered to the highest levels of compliance, reliability, and quality. The company is actively building partnerships across the energy and transportation sectors to accelerate the adoption of SAF on a global scale. XCF is listed on the Nasdaq Capital Market and trades under the ticker, SAFX. Current outstanding shares: ~153.2 million; 20% free float (as of August 26, 2025).

To learn more, visit www.xcf.global.

Contacts

XCF Global:
C/O Camarco
XCFGlobal@camarco.co.uk

Media:

Camarco
Andrew Archer | Rosie Driscoll | Violet Wilson
XCFGlobal@camarco.co.uk

Forward Looking Statements

This Press Release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “should”, “expect”, “intend”, “will”, “estimate”, “anticipate”, “believe”, “predict”, “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. These forward-looking statements, including, without limitation, statements regarding XCF Global’s expectations with respect to future performance and anticipated financial impacts of the recently completed business combination with Focus Impact BH3 Acquisition Company (the “Business Combination”), estimates and forecasts of other financial and performance metrics, and projections of market opportunity and market share, are subject to risks and uncertainties, which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by XCF Global and its management, are inherently uncertain and subject to material change. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: (1) changes in domestic and foreign business, market, financial, political, and legal conditions; (2) unexpected increases in XCF Global’s expenses resulting from potential inflationary pressures and rising interest rates, including manufacturing and operating expenses and interest expenses; (3) the occurrence of any event, change or other circumstances that could give rise to the termination of negotiations and any agreements with regard to XCF Global’s offtake arrangements; (4) the outcome of any legal proceedings that may be instituted against the parties to the Business Combination or others; (5) XCF Global’s ability to regain compliance with Nasdaq’s continued listing standards and thereafter continue to meet Nasdaq’s continued listing standards; (6) XCF Global’s ability to integrate the operations of New Rise and implement its business plan on its anticipated timeline; (7) XCF Global’s ability to raise financing in the future and the terms of any such financing; (8) the New Rise Reno production facility’s ability to produce the anticipated quantities of SAF without interruption or material changes to the SAF production process; (9) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its landlord with respect to the ground lease for the New Rise Reno facility; (10) XCF Global’s ability to resolve current disputes between its New Rise subsidiary and its primary lender with respect to loans outstanding that were used in the development of the New Rise Reno facility; (11) costs related to the Business Combination and the New Rise acquisitions; (12) the risk of disruption to the current plans and operations of XCF Global as a result of the consummation of the Business Combination; (13) XCF Global’s ability to recognize the anticipated benefits of the Business Combination and the New Rise acquisitions, which may be affected by, among other things, competition, the ability of XCF Global to grow and manage growth profitably, maintain relationships with customers and suppliers and retain its management and key employees; (14) changes in applicable laws or regulations; (15) risks related to extensive regulation, compliance obligations and rigorous enforcement by federal, state, and non-U.S. governmental authorities; (16) the possibility that XCF Global may be adversely affected by other economic, business, and/or competitive factors; (17) the availability of tax credits and other federal, state or local government support; (18) risks relating to XCF Global’s and New Rise’s key intellectual property rights; (19) the risk that XCF Global’s reporting and compliance obligations as a publicly-traded company divert management resources from business operations; (20) the effects of increased costs associated with operating as a public company; and (21) various factors beyond management’s control, including general economic conditions and other risks, uncertainties and factors set forth in XCF Global’s filings with the Securities and Exchange Commission (“SEC”), including the final proxy statement/prospectus relating to the Business Combination filed with the SEC on February 6, 2025, this Press Release and other filings XCF Global makes with the SEC in the future. If any of the risks actually occur, either alone or in combination with other events or circumstances, or XCF Global’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that XCF Global does not presently know or that it currently believes are not material that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect XCF Global’s expectations, plans or forecasts of future events and views as of the date of this Press Release. These forward-looking statements should not be relied upon as representing XCF Global’s assessments as of any date subsequent to the date of this Press Release. Accordingly, undue reliance should not be placed upon the forward-looking statements. While XCF Global may elect to update these forward-looking statements at some point in the future, XCF Global specifically disclaims any obligation to do so.

SOURCE: XCF Global, Inc.

View the original press release on ACCESS Newswire

Featured in: 20 Most Innovative Companies to Watch in 2025

CHICAGO, IL / ACCESS Newswire / August 26, 2025 / In a year dominated by artificial intelligence breakthroughs, generative design, and the race toward quantum codebases, one of the boldest innovations of 2025 does not come from a Silicon Valley lab. Instead, it comes from the pen of John C. Sturgess, a solo founder redefining masculinity through the power of narrative. His book, How a Boy Grows Up to Be a Man, has been hailed as a cultural milestone, placing him on the Global Radiance shortlist and securing his feature in the 20 Most Innovative Companies to Watch in 2025.

While most innovators are measured by patents, algorithms, or valuations, Sturgess introduces something rarer: a product built on storytelling as infrastructure. His innovation is emotional rather than mechanical, yet it disrupts with equal force. At its core, Sturgess’s work argues that emotional intelligence is the new intellectual property, a competitive advantage as crucial in leadership as in personal growth.

The Context of a Cultural Disruptor

Silicon Valley itself was once dismissed as a footnote, beginning with 18,000 high-tech jobs in 1959 and exploding to more than 268,000 by 1990. Its rise was fueled not just by transistors and silicon, but by mentorship, imagination, and an ability to question the status quo.

Sturgess mirrors that same DNA. Where the Valley scaled through microchips, he scales through ideas. Where engineers coded systems, he codes character. And while today’s generation is drowning in information overload, social media noise, and cultural fragmentation, Sturgess offers something strikingly rare: clarity, structure, and grounded wisdom.

A Solo Founder in the Marketplace of Identity

John C. Sturgess operates like a company of one. He is a one-man think tank, producing a body of work that functions simultaneously as memoir, manifesto, and manual for a generation uncertain about what manhood means in the 21st century.

His mission is not a marketing slogan. It is a blueprint. His book channels the voice of a wise uncle, seasoned mentor, and relentless founder rolled into one. He speaks with a tone that feels both timeless and urgent, offering men and the broader culture permission to rethink identity outside the narrow boxes of strength without sensitivity, leadership without empathy, or ambition without reflection.

“Innovation,” Sturgess says, “is not just about building tools for the outside world. It is about building frameworks for the inner life. If technology can rewire how we work, then wisdom can rewire how we live.”

Innovation Without Gadgets

What makes Sturgess especially disruptive is that his innovation is human-centered, not product-centered. In an era where consumer tech cycles move faster than cultural values, he has chosen to invest in a commodity that does not depreciate: perspective.

Instead of a device, Sturgess delivers a guide to becoming, a narrative that reframes how young men approach responsibility, identity, and growth. His work holds relevance not just for teenagers or college students, but also for entrepreneurs, executives, and fathers navigating leadership in every sphere of life.

By linking manhood to reflection, adaptability, and resilience, he positions identity as a competitive advantage that transcends industries. His stories are not nostalgia pieces. They are working frameworks for decision-making in an age of constant disruption.

Why Global Radiance Recognized Him

The 20 Most Innovative Companies to Watch in 2025 by Global Radiance highlights global leaders and groundbreaking organizations reshaping industries, culture, and thought leadership. Known for its focus on innovation that transcends borders, Global Radiance profiles figures who set the pace for the future.

Within that list, John C. Sturgess stands apart. He is not an enterprise, but a cultural startup whose impact radiates through philosophy rather than quarterly earnings. The selection committee cited his “ability to redefine innovation beyond technology, anchoring it in humanity.” His recognition proves that in the ever-expanding marketplace of influence, ideas can scale as effectively as hardware.

“Stay hungry, stay foolish,” Steve Jobs famously said. Sturgess embodies that ethos, encouraging men not just to achieve, but to evolve.

About John C. Sturgess

John C. Sturgess is an author, cultural thinker, and solo founder reimagining masculinity for a new era. His book, How a Boy Grows Up to Be a Man, has been called a disruptive guide to identity in a fractured world. Through narrative and reflection, Sturgess provides frameworks for resilience, emotional intelligence, and purpose. Recognized by Global Radiance in the 20 Most Innovative Companies to Watch in 2025, he continues to expand his reach as a voice for generational transformation.

About Global Radiance

Global Radiance is an international business and innovation magazine spotlighting transformative companies, leaders, and creators shaping the future of their industries. With a strong focus on visionary ideas, Global Radiance curates annual rankings such as the 20 Most Innovative Companies to Watch, cementing its reputation as a trusted voice in global thought leadership.

Media Contact

Team Editorial
Evrima Chicago, LLC
PR@EvrimaChicago.com
909-326-0347

About Evrima Chicago

Evrima Chicago is a PR and media firm specializing in editorial strategy, syndication, and public positioning for innovators, authors, and organizations. Acting as the PR and media contact for John C. Sturgess, Evrima Chicago provides end-to-end visibility campaigns that amplify his message, extend his reach, and build enduring media presence.

Disclaimer

• Role and capacity: Evrima Chicago serves as PR and media representative for John C. Sturgess. This notice is distributed for informational and media purposes.

• Independence and views: The views, statements, and claims attributed to John C. Sturgess are his own. They do not represent the views of Evrima Chicago, its principals, or affiliates.

• Editorial development: Evrima Chicago’s editorial team prepares and formats materials using cited, publicly available, or client-provided information. Drafting support may include copy editing, headline framing, and press-ready layout.

• Verification and sources: Factual assertions are based on sources deemed reliable at the time of publication. Where possible, citations or source descriptions are included or available on request.

• Recognition and listings: Any references to shortlists, awards, rankings, or features by third-party publications, including Global Radiance, are subject to those publishers’ independent criteria and editorial control.

• No endorsement: Mention of third parties, platforms, products, or services does not imply endorsement by Evrima Chicago. All trademarks and service marks are the property of their respective owners.

• Forward-looking statements: Some statements may be forward-looking and involve risks and uncertainties. Actual results may differ due to market conditions, editorial decisions by third parties, or other factors beyond the control of John C. Sturgess or Evrima Chicago.

• Conflicts of interest and sponsorships: Where paid placements, sponsored content, or advertising relationships exist, they will be labeled accordingly. Evrima Chicago discloses material relationships consistent with applicable guidelines.

• Corrections and updates: For corrections, clarifications, or updates, contact Evrima Chicago. We review bona fide requests promptly and update materials when warranted.

• Distribution and republication: Media outlets may excerpt this material with attribution. Edited or condensed versions should preserve meaning and context. The canonical version is available from Evrima Chicago upon request.

• Privacy: No personal data beyond publicly available or authorized information is included. Evrima Chicago handles any provided personal data in accordance with applicable laws.

• Contact: Media and interview requests, rights and permissions, or source documentation requests should be directed to Evrima Chicago, PR@EvrimaChicago.com, 909-326-0347. Editorial tips may also be sent to waasay@evrimachicago.com.

Evrima Chicago provides PR and media services to John C. Sturgess, including editorial strategy, press development, and syndication support to strengthen public positioning and long-term visibility.

SOURCE: Evrima Chicago LLC.

View the original press release on ACCESS Newswire

TORONTO, ON AND BREDA, THE NETHERLANDS / ACCESS Newswire / August 26, 2025 / Organto Foods Inc. (TSXV:OGO)(OTCQB:OGOFF)(FSE:OGF) (“Organto” or “the Company”), is pleased to announce its financial results for the three and six-month periods ended June 30, 2025. All amounts are expressed in Canadian dollars and in accordance with International Financial Reporting Standards (IFRS), except where specifically noted.

Hi-Lites

Quarter Ended June 30, 2025

• Second quarter sales of $17.2 million, an increase of 291% versus the prior year. Largest quarterly sales in the history of the Company and representing 83% of total fiscal 2024 sales of $20.7 million.

• Gross profit of $1.3 million, an increase of 352% versus the prior year. Largest quarterly gross profit dollars in the history of the Company.

• Cash operating expenses of 6.8% of sales versus 13.4% in the prior year. Cash operating costs as percentage of sales improved as business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.5) million, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

Six-Month Period Ended June 30, 2025

• Sales of $30.8 million, an increase of 241% versus the prior year, and already 49% greater than fiscal 2024 total sales of $20.7 million.

• Gross profit of $2.4 million, an increase of 325% versus the first six months of the prior year, and already 35% greater than fiscal 2024 total gross profit of $1.8 million.

• Cash operating expenses of 6.7% of sales versus 11.3% in the prior year. Cash operating costs as percentage of sales demonstrate continued improvement as the business scales and overheads are leveraged.

• EBITDA⁽¹⁾ (Earnings before interest, taxes, depreciation and amortization) of $(0.2) million versus $(0.5) in the prior year, reflecting improved operating results offset by the impact of losses on derivatives used to manage currency risk.

• Balance sheet significantly strengthened as a result of improved operations, debt restructuring and financing activities:

  • Working capital of $0.2 million versus negative working capital of $14.6 million at December 31, 2024.

  • Short-term loans and convertible debentures reduced to $2.5 million versus $12.5 million at December 31, 2024.

“We’re quite pleased with our results thus far in 2025, which we believe are a solid reflection of the strong momentum we are building in our business. These results are the result of the extensive restructuring and business realignment we’ve executed over the past 18 months, which we believe sets a solid foundation for sustained growth, stability, and a clear path to profitability. We are also very pleased to have completed a number of actions to strengthen our financial position including shares-for-debt settlements, conversion of our 8% convertible debentures into equity, extension of the maturity of our 10% convertible notes, and a series of successful private placements. The combination of our restructured and growing business and strengthened financial position, leads to our excitement as we work to build a world-class company serving growing healthy foods market, and in doing so creating lasting value for our partners, customers, team members and shareholders”, commented Steve Bromley, Co-Chair and Chief Executive Officer.

Fiscal 2025 Second Quarter Results Overview

• Sales of $17.2 million versus $4.4 million in the prior year, an increase of approximately 291%. Sales grew as new customers were added, while a number of existing customers increased their purchases. Q-2 sales represent the largest quarterly sales in the history of the Company and 83% of total fiscal 2024 sales of $20.7 million.

• Gross profit of $1.3 million or 7.4% of sales, versus $0.3 million or 6.4% of sales in the prior year, an increase of approximately 325% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $0.7 million or 4.1% of sales when accounting for the impact of realized currency hedging activities, versus $0.3 million or 5.8% of sales in the prior year.

• Cash operating expenses of $1.2 million or 6.8% of sales versus $0.6 million or 13.4% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, though have increased due to the assumption of operating expenses that were previously borne by the subsidiaries sold, as well as incremental costs to support the growth of our business.

• Loss from operations of $0.3 million versus a loss of $0.4 million in the prior year.

• Net loss for the period of $7.4 million after accounting for interest and accretion costs of $0.2 million and realized and unrealized losses on derivative assets and liabilities totaling $2.5 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.7 million and losses on the settlement of debt of $3.8 million. Net income in the prior year was $2.1 million, driven by a gain from the dissolution of one of the Company’s subsidiaries of $0.4 million and income related to the sale of three operating subsidiaries of $2.3 million, offset by losses related to continuing operations.

Fiscal 2025 Six-Month Results Overview

• Sales of $30.8 million versus $9.0 million in the prior year, an increase of approximately 241%. Sales have grown as new customers have been added, and a number of existing customers have increased their purchases. Six-month sales represent an increase of 49% over total fiscal 2024 sales of $20.7 million, which were previously the largest annual sales for the Company.

• Gross profit of $2.4 million or 7.7% of sales, versus $0.6 million or 6.2% of sales in the prior year, an increase of approximately 325% in gross profit dollars. Adjusted gross profit⁽¹⁾ was $1.8 million or 6.0% of sales when accounting for the impact of realized currency hedging activities, versus $0.5 million or 5.2% of sales in the prior year.

• Cash operating expenses of $2.1 million or 6.7% of sales versus $1.0 million or 11.3% of sales in the prior year. Operating expenses have stabilized following the sale of three subsidiaries in Q-2 2024, though have increased due to the assumption of operating expenses that were previously borne by the subsidiaries sold, as well as incremental costs to support the growth of our business.

• Loss from operations of $0.1 million versus a loss of $0.6 million in the prior year.

• Net loss for the period of $7.6 million after accounting for interest and accretion costs of $0.5 million and realized and unrealized losses on derivative assets and liabilities totaling $2.7 million. Net loss also includes a number of non-recurring costs including debt restructuring costs of $0.7 million and losses on the settlement of debt of $3.8 million. Net income in the prior year was $0.6 million, driven by a gain from the dissolution of one of our subsidiaries of $0.4 million and income related to the sale of three operating subsidiaries of $1.3 million, offset by losses related to continuing operations.

The Company’s filings, including Audited Financial Statements and accompanying Management’s Discussion and Analysis for the year ended December 31, 2024 are available at www.SEDARplus.ca or at the Company’s website at www.organto.com under the Investors tab.

Update on Private Placement

As previously announced on July 31 and August 19, the Company is in the process of closing a non-brokered private placement of 16,000,000 units at a price of $0.50 per unit, with each unit consisting of one common share and one-half common share purchase warrant. The warrants will be exercisable at $0.75 per share for 18 months, with acceleration rights if the share price reaches or exceeds $1.00 for ten consecutive trading days.

Proceeds from the private placement are intended to be used to continue the growth of the Company’s organic and fairtrade fruit and vegetable products, further develop the Company’s technology platform, and support general working capital requirements, and may also be used to repay part of the Company’s short-term debt.

ON BEHALF OF THE BOARD,

Steve Bromley
Co-Chair and Chief Executive Officer

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

For more information contact:

info@organto.com
John Rathwell, Senior Vice President, Corporate Development
647 629 0018

1. The information presented herein refers to the non-IFRS financial measures of adjusted gross profit and EBITDA. We hedge currencies for certain product categories where either the supply or sales commitments are fixed in foreign currencies. The gains and losses from these hedging activities are combined with gross profit to determine adjusted gross profit. We also refer to EBITDA, which is Earnings before interest, taxes, depreciation and amortization. These two measures are not recognized measures under IFRS and do not have a standardized meaning prescribed by IFRS. Non-IFRS financial measures should not be considered in isolation nor as a substitute for analysis of the Company’s financial information reported under IFRS and are unlikely to be comparable to similar measures presented by other issuers. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of the Company’s results of operations from management’s perspective and thus highlight trends in its business that may not otherwise be apparent when relying solely on IFRS measures. The Company believes that securities analysts, investors and other interested parties frequently use non-IFRS financial measures in the evaluation of the Company. The Company’s management also uses non-IFRS financial measures to facilitate operating performance comparisons from period to period and to prepare annual operating budgets and forecasts.

ABOUT ORGANTO FOODS

Organto is an integrated provider of branded, private label, and distributed organic and non-GMO fruit and vegetable products using a strategic asset-light business model to serve a growing socially responsible and health-conscious consumer around the globe. Organto’s business model is rooted in its commitment to sustainable business practices focused on environmental responsibility and a commitment to the communities where it operates, its people, and its shareholders.

FORWARD LOOKING STATEMENTS

This news release may include certain forward-looking information and statements, as defined by law including without limitation Canadian securities laws and the “safe harbor” provisions of the US Private Securities Litigation Reform Act of 1995 (“forward-looking statements”). In particular, and without limitation, this news release contains forward-looking statements respecting Organto’s business model and markets; Organto’s belief that the Company has made solid progress in the restructuring and realignment of its business focused on a clear path to profitability, sustained growth and long-term stability; Organto’s belief that the impact of these restructuring efforts is a key driver of its second quarter and six-month results; Organto’s belief that the combination of financing and debt restructuring efforts combined with strong sales and margin growth on a streamlined cost base positions the Company for an exciting future; Organto’s belief that it remains focused on building a world class company focused on growing healthy foods markets with the gaol of building shareholder value; management’s beliefs, assumptions and expectations; and general business and economic conditions. Forward-looking statements are based on a number of assumptions that may prove to be incorrect, including without limitation assumptions about the following: the ability and time frame within which Organto’s business model will be implemented and product supply will be increased; cost increases; dependence on suppliers, partners, and contractual counter-parties; changes in the business or prospects of Organto; unforeseen circumstances; risks associated with the organic produce business generally, including inclement weather, unfavorable growing conditions, low crop yields, variations in crop quality, spoilage, import and export laws, and similar risks; transportation costs and risks; general business and economic conditions; and ongoing relations with distributors, customers, employees, suppliers, consultants, contractors, and partners. The foregoing list is not exhaustive and Organto undertakes no obligation to update any of the foregoing except as required by law.

SOURCE: Organto Foods, Inc.

View the original press release on ACCESS Newswire

NEWARK, CALIFORNIA / ACCESS Newswire / August 26, 2025 / Protagonist Therapeutics, Inc. (“Protagonist” or the “Company”) today announced that Dinesh V. Patel, Ph.D., President and Chief Executive Officer, will participate in multiple investment bank conferences taking place in September.

Citi’s 2025 Biopharma Back to School Summit; Boston, MA – September 2-3, 2025
Format: Fireside Chat
Day/Time: Wednesday, September 3 at 9:45 A.M. ET
Webcast: https://kvgo.com/2025-biopharma-back-to-school-conference/protagonist-therapeutics-inc-sep-2025

H.C. Wainwright 27th Annual Global Investment Conference; New York, NY – September 8-10, 2025
Format: Fireside Chat
Day/Time: Tuesday, September 9 at 11:30 A.M. ET
Webcast: https://journey.ct.events/view/2f5c929c-0a3b-473f-a149-bcc3e8c0ed5f

BofA 11^th Annual World Medical Innovation Forum; Boston, MA – September 15-17, 2025
Panel Title: Immunology: Creating the next blockbuster in I&I
Day/Time: Tuesday, September 16

If you are interested in meeting with the Protagonist team during the conferences, please reach out to your respective conference representative.

A replay of the presentations will be available on the Company’s Investor Relations Events and Presentations webpage for one year following the event.

About Protagonist

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist’s proprietary discovery platform are currently in advanced Phase 3 clinical development, with New Drug Application (NDA) for icotrokinra submitted to the FDA in July and the NDA submission for rusfertide is expected by end of 2025. Icotrokinra (formerly, JNJ-2113), a first-in-class investigational targeted oral peptide that selectively blocks the Interleukin-23 receptor (“IL-23R”) is licensed to J&J Innovative Medicines (“JNJ”), formerly Janssen Biotech, Inc. Following icotrokinra’s joint discovery by Protagonist and JNJ scientists pursuant to the companies’ IL-23R collaboration, Protagonist was primarily responsible for the development of icotrokinra through Phase 1, with JNJ assuming responsibility for development in Phase 2 and beyond. Rusfertide, a mimetic of the natural hormone hepcidin, is currently in Phase 3 development for the rare blood disorder polycythemia vera (PV). Rusfertide is being co-developed and will be co-commercialized with Takeda Pharmaceuticals pursuant to a worldwide collaboration and license agreement entered in 2024 under which the Company remains primarily responsible for development through NDA filing. The Company also has a number of pre-clinical stage drug discovery programs addressing clinically and commercially validated targets, including IL-17 oral peptide antagonist PN-881, obesity triple agonist peptide PN-477, and the oral hepcidin program.

More information on Protagonist, its pipeline drug candidates and clinical studies can be found on the Company’s website at https://www.protagonist-inc.com/.

Investor Relations Contact

Corey Davis, Ph.D.
LifeSci Advisors
+1 212 915 2577
cdavis@lifesciadvisors.com

Media Contact

Virginia Amann, Founder/CEO
+1 833 500 0061 ext 1
ENTENTE Network of Companies
virginiaamann@ententeinc.com

SOURCE: Protagonist Therapeutics

View the original press release on ACCESS Newswire